Power Law company profile

Septerna

Biotech & Life Sciences · San Francisco, United States · Founded 2022 · IPO 2024 Colt

Biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs)

Valuation

$700M

Market cap · May/2026

Revenue

$46M

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Investors

16 investors on Septerna's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage

Catalio Capital Management

Casdin Capital

Samsara BioCapital

Logos Capital

Invus

BVF Partners

Third Rock Ventures

Series B+ 9 investors entered at this stage

Mirae Asset Capital

Monash University

Woodline Partners

Goldman Sachs Asset Management

Driehaus Capital Management

RA Capital Management

Vertex Ventures HC

Soleus Capital

Deep Track Capital

Global footprint

Where Septerna has talent and traffic

Workforce by country

🇺🇸 United States · San Francisco HQ

Book a demo for the full country breakdown

Web traffic by country

14K monthly visits
across markets

🇺🇸 United States47.1%

🇨🇳 China45%

🇮🇳 India7.9%

🇪🇸 Spain2.9%

Top 4 markets shown

Market sentiment

What the market is saying about Septerna

An AI-synthesized read of the highest-engagement posts about Septerna on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Septerna on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles